Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
In the blog post “What is multiple myeloma? Oncology Has It Backwards,” I try to make the point that multiple myeloma chemotherapy does more harm that good. Or at least standard-of-care chemotherapy regimens for multiple myeloma cause real short, long-term damage to MM patients.
Rather than administer toxic chemo regimens sparingly, conventional oncology hammers the typical patient with round after toxic round of chemo. I don’t think it is coincidence that the
Ever heard the phrase “the cure is worse than the disease?” Talk to a long term MM survivor after they’ve experienced a remission and relapse or two.
I admit that there are times in the life of a multiple myeloma patient when he/she may need toxic therapies to quell their MM. In other words, both the MM cancer itself, as well as toxic therapies will damage bones, kidneys, bone marrow, even our heart function.
Research and experience has taught me that MM patients and survivors have to walk the fine line between the damage caused by their multiple myeloma and the damage caused by chemotherapy and radiation given to treat their disease.
I don’t mean to imply that it is easy to walk this fine line much less identify the fine line…
In my opinion then, the solution to undergo those evidence-based, non-toxic therapies that are
According to the research linked and excerpted below, modified citrus pectin (MCP) can do of those things.
An example of what I am talking about would be a 3-4 courses of induction therapy followed by a vacation from toxicity. During this vacation, the patient undergoes
such as modified citrus pectin.
The months or years spend healing the damage done by your induction therapy should prepare you for more toxic therapy in case you ever relapse.
Have you been diagnosed with multiple myeloma? What stage were you at diagnosis? What symptoms were you experiencing when you were diagnosed?
To learn more about both conventional and non-conventional MM therapies, scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
“Here we show that GCS-100 induces apoptosis in various multiple myeloma cell lines, including those resistant to dexamethasone, melphalan, or doxorubicin.
Examination of purified patient multiple myeloma cells showed similar results. Specifically, GCS-100 decreases viability of bortezomib/PS-341-resistant multiple myeloma patient cells.
Importantly, GCS-100 inhibits multiple myeloma cell growth induced by adhesion to bone marrow stromal cells; overcome the growth advantage conferred by antiapoptotic protein Bcl-2, heat shock protein-27, and nuclear factor-kappaB; and blocks vascular endothelial growth factor-induced migration of multiple myeloma cells…
Combined with dexamethasone, GCS-100 induces additive anti-multiple myeloma cytotoxicity associated with mitochondrial apoptotic signaling via release of cytochrome c and Smac followed by activation of caspase-3.
Moreover, GCS-100 + dexamethasone-induced apoptosis in multiple myeloma cells is accompanied by a marked inhibition of an antiapoptotic protein Galectin-3, without significant alteration in Bcl-2 expression.”
“At a histological level, MCP clearly reduced renal cell proliferation but did not affect apoptosis. Later, during the recovery phase at two weeks, MCP-treated mice demonstrated reduced galectin-3 in association with decreased renal fibrosis, macrophages, pro-inflammatory cytokine expression and apoptosis.
Our data indicates that MCP is protective in experimental nephropathy with modulation of early proliferation and later galectin-3 expression, apoptosis and fibrosis.
This raises the possibility that MCP may be a novel strategy to reduce renal injury in the long term, perhaps via carbohydrate binding-related functions of galectin-3.
“Galectin-3 overexpression and secretion is associated with several diseases and is extensively studied in the context of fibrosis, heart failure, atherosclerosis and diabetes mellitus…
In this review, we summarize the function of galectin-3 in physiology and focus on its role in pathophysiological scenarios involving fibrosis, heart failure (HF), atherosclerosis and diabetes mellitus (DM)…”
“Modified citrus pectin (MCP) is known for its anti-cancer effects and its ability to be absorbed and circulated in the human body. In this report we tested the ability of MCP to induce the activation of human blood lymphocyte subsets like T, B and NK-cells…
MCP has immunostimulatory properties in human blood samples, including the activation of functional NK cells against K562 leukemic cells in culture. Unsaturated oligogalacturonic acids appear to be the immunostimulatory carbohydrates in MCP…”
“The anti-adhesive properties of MCP as well as its potential for increasing apoptotic responses of tumor cells to chemotherapy by inhibiting galectin-3 anti-apoptotic function are discussed in the light of a potential use of this carbohydrate-based substance in the treatment of multiple human malignancies…
MCP has been shown to be effective either in vitro or in vivo, or both, against prostate carcinoma,2–4 colon carcinoma,5,6 breast carcinoma,4,6,7 melanoma,1,8 multiple myeloma,9 and hemangiosarcoma.10…
Consequently, Gal-3 was shown to regulate directly sensitivity of cancer cells to various chemotherapeutic agents such as cisplatin,22,34,35staurosporine,22 etoposide,34 bortezomib,9 dexamethasone,9 and doxorubicin.10…